Palmitoylethanolamide (PEA)
Endogenous fatty acid amide with a meta-analysis signal for pain, though results varied by condition.
- Evidence
- Preliminary evidenceGRADE certainty: Low
- Typical dose
- Trials commonly used 300 mg three times daily of ultramicronised PEA
- Time to effect
- Benefit visible from about 4 to 6 weeks in pooled trials
- Safety
- Has documented cautions
Evidence ratings summarise published research on Palmitoylethanolamide (PEA) in general. They are not a health claim for any product and not advice for any individual. Talk to your doctor before starting anything new, especially if you take medication.
Ask about Palmitoylethanolamide (PEA)
Interactions
Taking any medication?
Check Palmitoylethanolamide (PEA) against it.
Why
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide, the saturated equivalent of the endocannabinoid anandamide. A 2025 meta-analysis of 18 RCTs (n=1,196) found lower pain than control across nociceptive, neuropathic and nociplastic conditions, with benefit visible from about 4 to 6 weeks, but results were not uniform: a 12-week RCT in spinal cord injury neuropathic pain found no difference from placebo, and a small pilot IBS trial used a PEA-polydatin combination product. Certainty is limited. Ultramicronised PEA is sold in Italy and other European countries for use under medical supervision.
How it works
Endogenous PPAR-α agonist with anti-inflammatory effects on mast cells, microglia, and astrocytes, distinct from cannabinoid receptor agonism. Modulates the 'entourage effect' on endocannabinoid signalling without binding CB1/CB2 directly.
Expected onset · Benefit visible from about 4 to 6 weeks in pooled trials
How to take
Dosage
Trials commonly used 300 mg three times daily of ultramicronised PEA. Higher doses (1,200 mg/day) used in some trials. Continue for at least 8 weeks before assessing.
Timing
Divided 2–3 times daily with meals
On the label
Ultramicronised PEA (um-PEA) is the form used in many trials; stated mg per dose.
Studied in
Adults with chronic pain discussing an add-on option with their clinician; trials report few side effects but are small.
Safety
Evidence
Viña and López-Moreno 2025 Nutrition Reviews meta-analysis (18 RCTs, n=1,196): PEA lowered pain versus control in nociceptive, neuropathic and nociplastic conditions, and quality of life was higher. Results were not uniform: a 12-week RCT in spinal cord injury neuropathic pain (n=68) found no difference from placebo, while a pilot IBS trial of a PEA-polydatin combination reported less abdominal pain.
GRADE certainty: Low — rated by Healicus using the GRADE method
- Viña I, López-Moreno M, Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding, Nutr Rev 2025
- Cremon C et al., Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome, Aliment Pharmacol Ther 2017
- Andresen SR et al., Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial, Pain 2016
Questions people ask
Does Palmitoylethanolamide (PEA) work?
Viña and López-Moreno 2025 Nutrition Reviews meta-analysis (18 RCTs, n=1,196): PEA lowered pain versus control in nociceptive, neuropathic and nociplastic conditions, and quality of life was higher. Results were not uniform: a 12-week RCT in spinal cord injury neuropathic pain (n=68) found no difference from placebo, while a pilot IBS trial of a PEA-polydatin combination reported less abdominal pain. Certainty of the evidence: Low, rated by Healicus using the GRADE method.
How is Palmitoylethanolamide (PEA) taken?
Trials commonly used 300 mg three times daily of ultramicronised PEA. Higher doses (1,200 mg/day) used in some trials. Continue for at least 8 weeks before assessing. Timing: Divided 2–3 times daily with meals. Ranges are those reported in the cited sources, not individual advice; talk to your doctor or pharmacist before starting, especially if you take medication.
Are there interactions or cautions?
Few side effects were reported across published trials. Mild GI upset rarely. Theoretical antiplatelet effect at very high doses. Pregnancy and breastfeeding data limited; coordinate with the prescribing clinician. Interaction data are limited. Documented drug and supplement interactions can be looked up in the free interaction reference.
What is the evidence based on?
Sources: Viña I, López-Moreno M, Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding, Nutr Rev 2025; Cremon C et al., Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome, Aliment Pharmacol Ther 2017; Andresen SR et al., Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial, Pain 2016.
One evidence finding a day, like this one: follow Healicus on Threads or Bluesky.